Leerink Partners Maintains Outperform on Aquestive Therapeutics, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has maintained an Outperform rating on Aquestive Therapeutics and raised its price target from $12 to $13.
October 25, 2024 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has maintained an Outperform rating on Aquestive Therapeutics and increased the price target from $12 to $13, indicating positive analyst sentiment.
The increase in price target from $12 to $13 by Leerink Partners suggests a positive outlook for Aquestive Therapeutics. Maintaining an Outperform rating indicates continued confidence in the company's performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100